MGRX Stock Financials: Financial Performance and Reports

Period	FY-2023	FY-2022	FY-2021
Period Ended	12/31/2023	12/31/2022	12/31/2021
Operating Revenue	$731,493.00	$8,939.00	$0.00
Cost of Revenue	$299,992.00	$4,089.00	$0.00
Gross Profit	$431,501.00	$4,850.00	$0.00
Gross Profit Ratio	0.59	0.54	0
Research and Development Expenses	$0.00	$0.00	$0.00
General & Administrative Expenses	$6.45 M	$2.00 M	$70,080.00
Selling & Marketing Expenses	$2.10 M	$352,860.00	-$52,560.00
Selling, General & Administrative Expenses	$9.65 M	$2.00 M	$17,520.00
Other Expenses	$6,473.00	$0.00	$0.00
Operating Expenses	$9.65 M	$2.00 M	$17,520.00
Cost And Expenses	$9.95 M	$2.00 M	$17,520.00
Interest Income	$0.00	$0.00	$0.00
Interest Expense	$0.00	$6,473.00	$181.00
Depreciation & Amortization	$24,889.00	$3,863.00	$70,080.00
EBITDA	-$9.19 M	-$1.99 M	-$17,520.00
EBITDA Ratio	-12.57	-222.36	0
Operating Income	-$9.22 M	-$1.99 M	-$17,520.00
Operating Income Ratio	-12.6	-222.8	0
Total Other Income/Expenses Net	$6,473.00	-$6,473.00	-$181.00
Income Before Tax	-$9.21 M	-$2.00 M	-$17,701.00
Income Before Tax Ratio	-12.59	-223.52	0
Income Tax Expense	$1.00	$0.00	-$70,080.00
Net Income	-$9.21 M	-$2.00 M	-$17,701.00
Net Income Ratio	-12.59	-223.52	0
EPS	-0.43	-0.12	-0.001
EPS Diluted	-0.43	-0.12	-0.001
Weighted Average Shares Out	$21.42 M	$17.32 M	$17.32 M
Weighted Average Shares Out Diluted	$21.42 M	$17.32 M	$17.32 M
Link

Mangoceuticals, Inc. (MGRX) Financials